Published 07-17-18
Issued by Teva Pharmaceuticals
Teva has a rich history of providing innovative, high-quality generic and specialty drugs and health solutions to patients around the world every day. Since joining the company late last year, I’ve been motivated by the opportunity to advance this legacy of promoting health.
A message from our CEO, Kåre Schultz
Teva has a rich history of providing innovative, high-quality generic and specialty drugs and health solutions to patients around the world every day. Since joining the company late last year, I’ve been motivated by the opportunity to advance this legacy of promoting health.
In December 2017, we launched a comprehensive restructuring program, crucial to restoring our financial security and stabilizing our business. We have also strengthened our leadership team and created a new organizational structure. These decisions were not taken lightly, but were necessary to enable us to better serve our patients while maintaining the highest standards of quality, ethics and compliance.
In these times of change, our commitment to Social Impact has not wavered. Social Impact is inherently embedded in our business, as Teva is uniquely positioned to improve health by offering accessible treatments to millions worldwide.
The world is facing dynamic health, environmental and social challenges. Together with our partners and stakeholders, we are committed to evolving and adapting our efforts to effect change in ways that are aligned with our business expertise and resources.
I encourage you to read about our Social Impact progress in this report and look forward to advancing these efforts together.
Kåre Schultz
President & CEO, Teva Pharmaceutical Industries Ltd.
Report Highlights
Teva is a leading global pharmaceutical company that delivers high-quality, patient-centric healthcare solutions used by millions of patients every day. Teva’s “2017 Social Impact Report: Improving Health, Enabling Better Days” spotlights the company’s commitment to corporate responsibility and transparency, and provides context on its efforts to contribute to healthy communities in ways the business can uniquely support—through safe medicines, collaboration, health initiatives and innovative research.
Media Contact Information:
Teva Pharmaceutical Industries Ltd.
IR Contacts
United States
Kevin C. Mannix, (215) 591-8912
or
Israel
Ran Meir, 972 (3) 926-7516
Tomer Amitai, 972 (3) 926-7656
PR Contacts
United States
Elizabeth DeLuca, (267) 468-4329
or
Israel
Yonatan Beker, 972 (54) 888-5898
Teva Pharmaceutical Industries Ltd. (NYSE and TASE:TEVA) is a leading global pharmaceutical company that delivers high-quality, patient-centric healthcare solutions to millions of patients every day. Headquartered in Israel, Teva is the world’s largest generic medicines producer, leveraging its portfolio of more than 1,000 molecules to produce a wide range of generic products in nearly every therapeutic area. In specialty medicines, Teva has a world-leading position in innovative treatments for disorders of the central nervous system, including pain, as well as a strong portfolio of respiratory products. Teva integrates its generics and specialty capabilities in its global research and development division to create new ways of addressing unmet patient needs by combining drug development capabilities with devices, services and technologies. Teva's net revenues in 2014 amounted to $20.3 billion. For more information, visit www.tevapharm.com.
More from Teva Pharmaceuticals